Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Sinopharm unit inches toward vaccine breakthrough

    By Liu Zhihua | China Daily | Updated: 2020-04-30 10:42
    Share
    Share - WeChat
    A China National Biotech Group Co Ltd employee displays a COVID-19 inactive vaccine, which is under development and trials, at the company's research institute in Wuhan, capital of Hubei province, on April 10. [Photo/Xinhua]

    State-owned CNBG teams up with partners to step up development of effective, lasting treatment for COVID-19

    Chinese State-owned pharmaceutical giant Sinopharm Group has made substantial progress in developing vaccine candidates for the novel coronavirus that causes COVID-19.

    China National Biotech Group Co Ltd, Sinopharm's vaccine and bioscience unit, announced on Monday that its second inactivated vaccine targeting the contagion won clinical trial approval from the National Medical Products Administration. The vaccine is codeveloped by a unit under CNBG-Beijing Institute of Biological Products Co Ltd-and the Chinese Center for Disease Control and Prevention.

    On Friday, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by its unit, the Wuhan Institute of Biological Products, along with the Wuhan Institute of Virology under the Chinese Academy of Sciences.

    Approved for clinical trials on April 12, the vaccine was the first inactivated vaccine worldwide to reach such a developed approval stage. The NMPA authorized its phase-1 and phase-2 human trials at the same time on that day through a fast-track channel based on solid results from preclinical trial studies.

    "The world is racing to develop COVID-19 vaccines, yet it is not a competition between countries, but rather a race between humans and the virus," said Yang Xiaoming, president of CNBG.

    Yang said it is quite encouraging to have developed inactivated vaccines against COVID-19.

    Inactivated vaccines use nonliving viruses, bacteria or other pathogens that have lost disease-producing capacity to stimulate the immune system to develop an immune response.

    Wang Junzhi, an academic at the Chinese Academy of Engineering, said China has laid a solid foundation to research inactivated vaccines in recent years, and inactivated vaccines have been widely used to fight hepatitis A, influenza, poliomyelitis, and hand, foot and mouth disease.

    Yang added that China has distinctive advantages in developing vaccines against the disease thanks to the country's institutional features that can unite resources and efforts of different participants to concentrate on a specific program and target.

    1 2 3 Next   >>|
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    亚洲AV永久无码精品网站在线观看| 人妻无码αv中文字幕久久| 亚洲国产午夜中文字幕精品黄网站| 亚洲欧美中文日韩V在线观看| 欧美日韩中文在线| 亚洲人成无码久久电影网站| 亚洲国产人成中文幕一级二级 | 中文字幕亚洲综合久久菠萝蜜| 人妻少妇精品无码专区动漫| 精品久久久久久无码中文字幕| 天堂资源8中文最新版| 天堂资源在线最新版天堂中文| 内射无码午夜多人| A∨变态另类天堂无码专区| 欧美日本道中文高清| 久久久久久亚洲AV无码专区| 亚洲av永久无码制服河南实里| 亚洲人成无码www久久久| 国产乱妇无码大片在线观看| 亚洲欧美中文日韩在线v日本| YW尤物AV无码国产在线观看| 精品久久久久久无码中文野结衣| 最近中文字幕在线中文高清版| 国产午夜无码片免费| 少妇人妻无码专区视频| 亚洲AV无码成人精品区在线观看 | 日本精品久久久久中文字幕| 中文日韩亚洲欧美字幕| 亚洲AV无码成人精品区狼人影院 | av无码免费一区二区三区| 亚洲中文字幕无码专区| 欧美麻豆久久久久久中文| 日本乱中文字幕系列观看| 波多野结衣中文字幕免费视频| 永久免费无码日韩视频| 成?∨人片在线观看无码| 无码国产精品一区二区免费3p| 亚洲动漫精品无码av天堂| 亚洲日本中文字幕区| 精品一区二区三区中文字幕| 亚洲欧美在线一区中文字幕|